Revolve Wealth Partners LLC Has $498,000 Stake in Pfizer Inc. (NYSE:PFE)

Revolve Wealth Partners LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 12.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,766 shares of the biopharmaceutical company’s stock after buying an additional 2,087 shares during the period. Revolve Wealth Partners LLC’s holdings in Pfizer were worth $498,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Buffington Mohr McNeal acquired a new stake in Pfizer in the 4th quarter valued at $331,000. Diamant Asset Management Inc. grew its holdings in shares of Pfizer by 19.4% in the 4th quarter. Diamant Asset Management Inc. now owns 10,165 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 1,650 shares in the last quarter. Cascade Investment Advisors Inc. increased its position in shares of Pfizer by 5.4% in the fourth quarter. Cascade Investment Advisors Inc. now owns 63,144 shares of the biopharmaceutical company’s stock valued at $1,675,000 after acquiring an additional 3,235 shares during the last quarter. BankPlus Wealth Management LLC bought a new stake in Pfizer during the fourth quarter worth about $398,000. Finally, Lebenthal Global Advisors LLC boosted its position in Pfizer by 40.6% during the fourth quarter. Lebenthal Global Advisors LLC now owns 26,901 shares of the biopharmaceutical company’s stock valued at $714,000 after purchasing an additional 7,765 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Up 2.9 %

PFE stock opened at $26.86 on Tuesday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a market capitalization of $152.19 billion, a PE ratio of 36.29, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company’s 50-day simple moving average is $26.11 and its 200 day simple moving average is $27.94. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the business posted ($0.17) EPS. The business’s revenue was up 31.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.40%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 227.03%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PFE. Guggenheim dropped their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.